Far Infrared Treatment for Alzheimer's Disease

August 14, 2009 updated by: GAAD Medical Research Institute Inc.

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.

Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal.

Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.

Study Type

Interventional

Enrollment (Actual)

4

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Ontario
      • Toronto, Ontario, Canada, M4V 1L5
        • The Centre for Incurable Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • People with Alzheimer's disease

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NON_RANDOMIZED
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: 1
Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared radiation for 30 to 40 minutes per treatment session.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Management and Cure of Alzheimer's Disease
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Time Frame
Management and Cure of Dementia
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

GAAD Medical Research Institute Inc.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2008

Primary Completion (ANTICIPATED)

March 1, 2009

Study Completion (ANTICIPATED)

April 1, 2009

Study Registration Dates

First Submitted

January 11, 2008

First Submitted That Met QC Criteria

January 11, 2008

First Posted (ESTIMATE)

January 23, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

August 17, 2009

Last Update Submitted That Met QC Criteria

August 14, 2009

Last Verified

August 1, 2009

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • GAAD-AD-CTP1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer Disease

Clinical Trials on Far Infrared Radiation (5μm to 20μm wavelength)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Korea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe